USPHU.S. Physical Therapy, Inc.

$84.72+10% 1Y

$84.72

$58.5752 weeks$91.35

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in and cheap vs its sector, but at the top of its own P/E range.

2 good, 1 to watch

What the price assumes~+2% a year

Priced for ~2% a year FCF growth. The price demands less than its three-year revenue growth of 12% a year, expectations look modest.

Vs its own P/E rangedearest in 40 quartersderived

Expensive vs its own history: P/E 145.9 vs a 42.2 median over 40 quarters (+246% vs median).

Vs sector (EV/EBIT)15.7×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What USPH's price assumes

Today's price asks for 2.5% free cash flow growth a year; over the last three years U.S. Physical Therapy, Inc. delivered 1.3%, the price is ahead of the record.

1.24

Price / sales · no trailing P/E on file: measured against sales instead

Free cash flow yield: 6.3%
Free cash flow yield · Medical Care Facilities median 7.1%
Growth the price implies: +2.5%
Growth the price implies · The price pays for +2.5% free cash flow growth a year for a decade; the business has delivered +1.3% a year over the last three.
Price / book: 2.25
Price / book · today's price, trailing year to Jun 30, 2026